Suicidal Behavior and Severe Neuropsychiatric Disorders Following Glucocorticoid Therapy in Primary Care
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The incidence and the risk of suicidal behaviors and severe neuropsychiatric disorders in people treated with systemic glucocorticoids are poorly known. The authors assessed the incidence rates of depression, mania, delirium, panic disorder, and suicidal behaviors in patients treated with glucocorticoids in primary care settings and the risk factors for developing these outcomes. METHOD: Data were obtained for all adult patients registered between 1990 and 2008 at U.K. general practices contributing to The Health Improvement Network (THIN) primary care database. The incidence rates for the outcomes of interest were assessed in patients who received prescriptions for oral glucocorticoids and compared with those in patients who did not receive such prescriptions. The predictors of these outcomes in exposed patients were ascertained using Cox proportional hazards models. RESULTS: Overall, 786,868 courses of oral glucocorticoids were prescribed for 372,696 patients. The authors identified 109 incident cases of suicide or suicide attempt and 10,220 incident cases of severe neuropsychiatric disorders in these patients. The incidence of any of these outcomes was 22.2 per 100 person-years at risk for first-course treatments. Compared to people with the same underlying medical disease who were not treated with glucocorticoids, the hazard ratio for suicide or suicide attempt in exposed patients was 6.89 (95% CI=4.52–10.50); for depression, 1.83 (95% CI=1.72–1.94); for mania, 4.35 (95% CI=3.67–5.16); for delirium, confusion, or disorientation, 5.14 (95% CI=4.54–5.82); and for panic disorder, 1.45 (95% CI=1.15–1.85). Older men were at higher risk of delirium/confusion/disorientation and mania, while younger patients were at higher risk of suicide or suicide attempt. Patients with a previous history of neuropsychiatric disorders and those treated with higher dosages of glucocorticoids were at greater risk of neuropsychiatric outcomes. CONCLUSIONS: Glucocorticoids increase the risk of suicidal behavior and neuropsychiatric disorders. Educating patients and their families about these adverse events and increasing primary care physicians' awareness about their occurrence should facilitate early monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two meta-analyses 64,65 concluded that cortisol levels in MDD were elevated, with a moderate effect size.”
From Major depressive disorder (2016) · cites this paper as [65]
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847 · cited 1×
“Natural glucocorticoids such as cortisol affect behavior, mood, and other CNS-related processes (1).”
BackgroundDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109
Psychiatric Adverse Effects of Corticosteroids
Warrington, T. P., & Bostwick, J. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.10.1361 · Cited by 611
Lewis, J. D., Schinnar, R., Bilker, W. B., Wang, X., & Strom, B. L. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1335 · Cited by 602
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Steroid-induced psychiatric syndromes
Lewis, D. A., & Smith, R. E. (1983) · Journal of Affective Disorders · doi:10.1016/0165-0327(83)90022-8 · Cited by 528
The Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Walsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Research works printed but not linked: 2
- CSD Medical Research/EPIC, 2007, THIN Data From EPIC: A Guide for Researchers
- Reckart MD, 1990, Int J Psychosom, 37, 57
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
Corticosteroid-related central nervous system side effects
Ciriaco, M., Ventrice, P., Russo, G., Scicchitano, M., Mazzitello, G., Scicchitano, F., & Russo, E. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.120975 · Cited by 244
“[13] In particular, in the CNS, glucocorticoids exert their potential effects at hippocampal level, a structure intimately involved in the limbic system, which provides the processing of emotional information and memory.[14] Various studies show a correlation between high levels of endogenous cortisol and hippocampal…”
Genomic and epigenomic mechanisms of glucocorticoids in the brain
Gray, J. D., Kogan, J. F., Marrocco, J., & McEwen, B. S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.97 · Cited by 242
Basic and Clinical Pharmacology of Glucocorticosteroids
Becker, D. E. (2013) · Anesthesia Progress · doi:10.2344/0003-3006-60.1.25 · Cited by 233
“High dosages should probably be avoided in patients suffering psychoses or other severe affective disorders.(20)”
BackgroundAdverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects
Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., Bulloch, K., Cidlowski, J. A., Ronald de Kloet, E., Fardet, L., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13091264 · Cited by 230
“(6) found that women were more likely than men to develop depression during initiation of oral glucocorticoid treatment, while men were more likely to develop mania or delirium, confusion, or disorientation.”
Self-citationTreating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
From Receptor Balance to Rational Glucocorticoid Therapy
de Kloet, E. R. (2014) · Endocrinology · doi:10.1210/en.2014-1048 · Cited by 208
“” Their discovery heralded the treatment of patients suffering from inflammatory and autoimmune disorders with synthetic glucocorticoids, currently for about 1% of people in the Western world (141).”
BackgroundPrevention and management of glucocorticoid-induced side effects: A comprehensive review
Caplan, A. S., Fett, N. M., Rosenbach, M. A., Werth, V. P., & Micheletti, R. G. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.062 · Cited by 178
Chronopharmacology of glucocorticoids
Scherholz, M. L., Schlesinger, N., & Androulakis, I. P. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.004 · Cited by 144
Glucocorticoid and Mineralocorticoid Receptors in the Brain: A Transcriptional Perspective
Koning, A.-S. C. A. M., Buurstede, J. C., van Weert, L. T. C. M., & Meijer, O. C. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00158 · Cited by 140
“A recent argument for a direct effect of MR activation on mood comes from the use of synthetic glucocorticoid medication, which is known to cause adverse psychological, behavioral and cognitive effects [19, 20].”
BackgroundPrevention and management of glucocorticoid-induced side effects: A comprehensive review
Caplan, A., Fett, N., Rosenbach, M., Werth, V. P., & Micheletti, R. G. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.02.1241 · Cited by 168
Jones, J. R., Chaturvedi, S., Granados-Fuentes, D., & Herzog, E. D. (2021) · Nature Communications · doi:10.1038/s41467-021-25959-9 · Cited by 144
Psychiatric symptoms in glioma patients: from diagnosis to management
Boele, F. W., Rooney, A. G., Grant, R., & Klein, M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s65874 · Cited by 155
“Nevertheless, the use of glucocorticoids such as dexamethasone, which is often prescribed in glioma patients, increases the risk for suicide or suicide attempt, depression, and panic disorder considerably.(62) From the epilepsy literature, we know that suicidal thoughts can co-occur after temporal lobe surgery.”
Neuroinflammation in suicide: Toward a comprehensive model
Courtet, P., Giner, L., Seneque, M., Guillaume, S., Olie, E., & Ducasse, D. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1054879 · Cited by 146
“Long-term oral glucocorticoid therapy increases the risk of depression and SB (Fardet et al. 2012), both during treatment and withdrawal (Felger and Lotrich 2013).”
BackgroundCorticosteroids and Transition to Delirium in Patients With Acute Lung Injury*
Schreiber, M. P., Colantuoni, E., Bienvenu, O. J., Neufeld, K. J., Chen, K.-F., Shanholtz, C., Mendez-Tellez, P. A., & Needham, D. M. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000247 · Cited by 119
“However, of the 898 days on which a corticosteroid was administered, 72% of these days were at or above the dosing threshold previously associated with neuropsychiatric complications (50, 51) and this may have precluded our ability to identify a dose-response relationship.”
BackgroundInfluentialDelirium in the Intensive Care Unit: Incidence, risk factors, and impact on outcome
Tilouche, N., Hassen, M. F., Ali, H. B. S., Jaoued, O., Gharbi, R., & Atrous, S. (2018) · Indian Journal of Critical Care Medicine · doi:10.4103/ijccm.ijccm_244_17 · Cited by 125
Bénard-Laribière, A., Pariente, A., Pambrun, E., Bégaud, B., Fardet, L., & Noize, P. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-015905 · Cited by 111
“Moreover, short-term and mid-term users (who represented 98% of the cohort) are also at risk, as neuropsychiatric symptoms could emerge within a few days or weeks of starting the treatment.(25) Another key result is the apparently inappropriate prescribing of therapeutic measures associated with GC therapy.”
BackgroundSelf-citationTreatment-Resistant Depression Revisited: A Glimmer of Hope
Halaris, A. E., Sohl, E., & Whitham, E. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020155 · Cited by 110
“This study of over 350,000 primary care patients showed that even when the underlying medical illness is controlled for, patients treated with synthetic glucocorticoids are 7 times more likely to attempt suicide, and twice more likely to develop MDD [25].”
BackgroundEwald, E. R., Wand, G. S., Seifuddin, F., Yang, X., Tamashiro, K. L., Potash, J. B., Zandi, P., & Lee, R. S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.003 · Cited by 105
“…to glucocorticoids is a robust risk factor for neuropsychiatric illnesses and cognitive decline, as numerous lines of evidence implicate exposure to stress or glucocorticoids in the etiology of several psychiatric disorders (McEwen and Gianaros, 2010, Fardet et al., 2012, Theall et al., 2012).”
Backgroundde Kloet, E. R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.053 · Cited by 98
Boele, F. W., Klein, M., Verdonck-de Leeuw, I. M., Cuijpers, P., Heimans, J. J., Snijders, T. J., Vos, M., Bosma, I., Tijssen, C. C., Reijneveld, J. C., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2712-5 · Cited by 88
Environmental Stressors and Epigenetic Control of the Hypothalamic-Pituitary-Adrenal Axis
Lee, R. S., & Sawa, A. (2014) · Neuroendocrinology · doi:10.1159/000369585 · Cited by 79
Stress and coping in women with breast cancer:unravelling the mechanisms to improve resilience
Borgi, M., Collacchi, B., Ortona, E., & Cirulli, F. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.10.011 · Cited by 90
Lu, S., Wei, N., Jiang, J., Wu, L., Sheng, J., Zhou, J., Fang, Q., Chen, Y. Z., Zheng, S., Chen, F., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.031 · Cited by 78
“Previous findings observed that corticosteroids therapy had 4-to-5 fold higher risk of developing mania, following a dose-response correlation, increased with the magnitude of the initial daily dose (Fardet et al., 2012).”
Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations
Alcubierre, D. D., Ferrari, D., Mauro, G. C. D., Isidori, A. M., Tomlinson, J., & Pofi, R. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02091-7 · Cited by 79
“APSEs rarely occur at PRED-equivalent doses of 20 mg/day [262], but doses above 40 mg PRED-equivalent per day exhibit the highest risk of acute events [263] up to a proper “ steroid induced psychosis ”.”
BackgroundImproving Depression Outcome by Patient-Centered Medical Management
Rush, A. J., & Thase, M. E. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18040398 · Cited by 76
Multidimensional gender discrimination in workplace and depressive symptoms
Kim, G., Kim, J., Lee, S., Sim, J., Kim, Y., Yun, B., & Yoon, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234415 · Cited by 76
“Genetic factors [13], low birth weights [14], and immune related therapy involving the interferon and glucocorticoid systems [15, 16] are also associated with depression.”
BackgroundNeuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis
Koning, A.-S. C. A. M., van der Meulen, M., Schaap, D., Satoer, D., Vinkers, C. H., van Rossum, E. F. C., van Furth, W. R., Pereira, A. M., Meijer, O. C., & Dekkers, O. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad701 · Cited by 72
Lee, R. S., Oswald, L. M., & Wand, G. S. (2018) · Alcohol research · doi:10.35946/arcr.v39.2.05 · Cited by 72
Glucocorticoid Therapy and Adrenal Suppression
Nicolaides, N. C., Pavlaki, A. N., Alexandra, M. A. M., & Chrousos, G. P. (2011) · Europe PMC (PubMed Central) · Cited by 71
Epigenetics and Suicidal Behavior Research Pathways
Turecki, G. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.06.011 · Cited by 70
Mind and body: how the health of the body impacts on neuropsychiatry
Renoir, T., Hasebe, K., & Gray, L. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00158 · Cited by 72
“Therapeutic administration of high doses of corticosteroids has been associated with the development of a manic behavioral state (Warrington and Bostwick, 2006; Kenna et al., 2011; Fardet et al., 2012).”
BackgroundGibson, A. W., & Graber, J. J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-509 · Cited by 67
“These steroids are effective but can induce numerous neuropsychiatric symptoms including depression, anxiety, dysphoria, mania, delirium, insomnia, increased appetite, and cognitive deficits (167-169).”
BackgroundAyorech, Z., Tracy, D. K., Baumeister, D., & Giaroli, G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.015 · Cited by 62
“Steroidal antiinflammatory agents were excluded given that evidence supports an increased risk of iatrogenic mania (Fardet et al., 2012; Schäcke et al., 2002).”
BackgroundSteroid-induced mental disorders in cancer patients: a systematic review
Ismail, M. F., Lavelle, C., & Cassidy, E. (2017) · Future Oncology · doi:10.2217/fon-2017-0306 · Cited by 63
Systemic glucocorticoid use in Denmark: a population-based prevalence study
Laugesen, K., Jørgensen, J. O. L., Sørensen, H. T., & Petersen, I. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015237 · Cited by 61
“They also are associated with increased risk of osteoporosis(9) and neuropsychiatric disorders.(10) Current knowledge of GC utilisation patterns is in need of updating and expansion.”
BackgroundSelf-citationRisk of Psychiatric Adverse Events Among Montelukast Users
Sansing‐Foster, V., Haug, N. R., Mosholder, A. D., Cocoros, N. M., Bradley, M. C., Ma, Y., Pennap, D. D., Dee, E., Toh, S., Pestine, E., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.07.052 · Cited by 59
Genetic Moderation of Stress Effects on Corticolimbic Circuitry
Bogdan, R., Pagliaccio, D., Baranger, D. A. A., & Hariri, A. R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.216 · Cited by 58
“…al, 2009), human studies indicate that chronic HPA axis stimulation (eg, for the treatment of medical conditions such as asthma or rheumatoid arthritis) can induce severe psychiatric symptoms that remit following treatment cessation (Fardet et al, 2012; Patten and Neutel, 2000; Wada et al, 2000).”
BackgroundAlbert, D., Belsky, D. W., Crowley, D. M., Latendresse, S. J., Aliev, F., Riley, B., Sun, C., Conduct Problems Prevention Research Group, Dick, D. M., & Dodge, K. A. (2015) · Journal of Policy Analysis and Management · doi:10.1002/pam.21811 · Cited by 47
Clinical Relevance of Steroid Use in Neuro-Oncology
Ly, I., & Wen, P. Y. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0713-6 · Cited by 54
Hippocampal volume in patients with asthma: Results from the Dallas Heart Study
Carlson, S. M., Kim, J., Khan, D. A., King, K. S., Lucarelli, R. T., McColl, R. W., Peshock, R. M., & Brown, E. S. (2016) · Journal of Asthma · doi:10.1080/02770903.2016.1186174 · Cited by 50
“, delirium) with prescription corticosteroids [47].”
Paul, S. N., Wingenfeld, K., Otte, C., & Meijer, O. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15835 · Cited by 49
Hippocampal Volume in Healthy Controls Given 3-Day Stress Doses of Hydrocortisone
Brown, E. S., Jeon‐Slaughter, H., Lu, H., Jamadar, R., Issac, S., Shad, M. U., Denniston, D., Tamminga, C. A., Nakamura, A., & Thomas, B. P. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.307 · Cited by 48
Morin, C., & Fardet, L. (2015) · Clinical Rheumatology · doi:10.1007/s10067-015-2953-7 · Cited by 48
“In a previous study of more than 370,000 patients exposed to systemic glucocorticoids, the risk of depression, mania, and confusion/delirium increased with age contrary to this of panic disorders or suicidality [13].”
BackgroundSelf-citationThe Neuroscience of Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205 · Cited by 45
Lee, R. S., Mahon, P. B., Zandi, P. P., McCaul, M. E., Yang, X., Bali, U., & Wand, G. S. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.07.003 · Cited by 40
“, 2006; Hackett and Steptoe, 2016; Kelly and Ismail, 2015) The brain is especially susceptible to cortisol, as prolonged exposure is associated with an increase in neuropsychiatric disorders,(Fardet et al., 2012) decrease in hippocampal volume, (Rahman et al.”
BackgroundWest, S., & Kenedi, C. (2014) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000065 · Cited by 44
Side Effects of Glucocorticoids
ALAN, İ. S., & Alan, B. (2018) · InTech eBooks · doi:10.5772/intechopen.72019 · Cited by 42
“Older patients appear to be more sensitive to memory impairment with short-term exposure [149].”
van der Meulen, M., Amaya, J. M., Dekkers, O. M., & Meijer, O. C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062446 · Cited by 41
“10 11 In addition, on an anatomical level, both preclinical and clinical studies have shown long-lasting effects of glucocorticoid overexposure on the brain.”
Meijer, O. C., & de Kloet, E. R. (2016) · Endocrinology · doi:10.1210/en.2016-1495 · Cited by 41
Zhang, F., Zhu, X., Yu, P., Sheng, T., Wang, Y., & Ye, Y. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105343 · Cited by 39
Miśkiewicz, P., Kryczka, A., Ambroziak, U., Żelazowska‐Rutkowska, B., Główczyńska, R., Opolski, G., Kahaly, G. J., & Bednarczuk, T. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0056 · Cited by 38
“bility, alteration of behaviour and panic attacks to more serious mood disorders, depression, suicide attempts, psychosis and delirium can occur in patients treated with glucocorticoids (GCS) [57, 58] with and without a previous history of such diseases [59].”
BackgroundArango-Lievano, M., Peguet, C., Catteau, M., Parmentier, M., Wu, S. H., Chao, M. V., Ginsberg, S. D., & Jeanneteau, F. D. (2016) · Scientific Reports · doi:10.1038/srep37231 · Cited by 39
“Dendritic segments included in the analyses met the following criteria: (1) be parallel or at acute angles relative to the coronal surface of sections to allow unambiguous identification of spines, (2) segments had no overlap with other branches, (3) dendritic segments from apical tree were imaged within the first 100…”
BackgroundCorticosteroids and Their Use in Respiratory Disorders
Janahi, I. A., Rehman, A., & Baloch, N. U.-A. (2018) · InTech eBooks · doi:10.5772/intechopen.72147 · Cited by 38
“Corticosteroids have also been shown to have a number of adverse effects on the central nervous system, especially when used in high doses [232].”
BackgroundMortality in adult patients with chronic spontaneous urticaria: A real-world cohort study
Kolkhir, P., Bieber, K., Hawro, T., Kridin, K., Ludwig, M. A., Olbrich, H., Metz, M., Vorobyev, A., Ludwig, R. J., & Maurer, M. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.11.036 · Cited by 36
Arcego, D. M., Buschdorf, J. P., O’Toole, N., Wang, Z., Barth, B., Pokhvisneva, I., Rayan, N. A., Patel, S. H., Filho, E. J. D. M., Lee, P., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.06.028 · Cited by 36
“The clinical use of glucocorticoids is associated with the development of psychiatric symptoms, including psychosis (4, 87-92).”
Cross, R. K. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001261 · Cited by 36
Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist
Galati, A., Brown, E. S., Bove, R. M., Vaidya, A., & Gelfand, J. M. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120004 · Cited by 35
Ricoux, A., Guitteny-Collas, M., Sauvaget, A., Delvot, P., Pottier, P., Hamidou, M. A., & Vanelle, J. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.12.011 · Cited by 35
Partington, R. J., Müller, S., Mallen, C. D., Sultan, A. A., & Helliwell, T. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.05.003 · Cited by 32
Rapid Reversal of Corticosteroid-Induced Mania with Sodium Valproate: A Case Series of 20 Patients
Roxanas, M. G., & Hunt, G. E. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.06.006 · Cited by 32
Carreira, H., Williams, R., Strongman, H., & Bhaskaran, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029227 · Cited by 32
Non-psychotropic medication and risk of suicide or attempted suicide: a systematic review
Gorton, H. C., Webb, R. T., Kapur, N., & Ashcroft, D. M. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009074 · Cited by 31
“Glucocorticoids are often introduced during disease relapse which could contribute to suicide risk, even when indication is controlled for.(36) Likewise, the increased suicide risk identified prior to initiation of isotretinoin, could be a factor of acne severity.”
BackgroundGlucocorticoid-Mediated Developmental Programming of Vertebrate Stress Responsivity
Gans, I. M., & Coffman, J. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.812195 · Cited by 31
Hardy, J. R., Haywood, A., Rickett, K., Sallnow, L., & Good, P. D. (2021) · Palliative Medicine · doi:10.1177/0269216320986717 · Cited by 30
Lightman, S., & Terry, J. R. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70182-7 · Cited by 28
The physiology of stress and the human body’s response to stress
Lee, R. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823039-8.00017-4 · Cited by 28
Systems Medicine: Physiological Circuits and the Dynamics of Disease
Alon, U. (2023) · doi:10.1201/9781003356929 · Cited by 27
Cross-species Association Between Telomere Length and Glucocorticoid Exposure
Lee, R. S., Zandi, P. P., Vives, A. S., Aulinas, A., Carey, J. L., Webb, S. M., McCaul, M. E., Resmini, E., & Wand, G. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab519 · Cited by 27
Hultcrantz, M. L., Svensson, T., Derolf, Å. R., Kristinsson, S. Y., Lindqvist, E. K., Ekbom, A., Granath, F. N., & Björkholm, M. (2014) · Cancer Medicine · doi:10.1002/cam4.316 · Cited by 27
“Also, the treatment can have a negative impact on quality of life; high doses of corticosteroids, included in most MM treatment regimen, can induce depression and psychosis and thus enhance the risk of suicide/suicide attempt [22, 23].”
BackgroundNeuropsychiatric symptoms in lupus
Lynall, M.-E. (2018) · Lupus · doi:10.1177/0961203318801672 · Cited by 26
Yoga in major depressive disorder: molecular mechanisms and clinical utility
Tolahunase, M., Gautam, S., Sagar, R., Kumar, M., & Dada, R. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s553 · Cited by 26
“Same authors have also reported the occurrence of severe neuropsychiatric outcomes including depression following discontinuation of long-term glucocorticoid therapy [89].”
BackgroundImmunosuppression following organ transplantation. Part 1: mechanisms and immunosuppressive agents
Cajanding, R. J. M. (2018) · British Journal of Nursing · doi:10.12968/bjon.2018.27.16.920 · Cited by 26
Genome‐wide DNA methylation investigation of glucocorticoid exposure within buccal samples
Braun, P., Tanaka‐Sahker, M., Chan, A. C., Jellison, S. S., Klisares, M. J., Hing, B. W. Q., Shabbir, Y., Gaul, L. N., Nagahama, Y., Robles, J., et al. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12835 · Cited by 26
“Individuals treated with GC had an elevated risk of suicide or suicide attempt, depression, mania, delirium, and panic disorder.(14) This is consistent with the hypothesis that the impact of stress on psychiatric disorders is mediated in part by GC exposure.”
BackgroundDevelopmental mediation of genetic variation in response to the Fast Track prevention program
Albert, D., Belsky, D. W., Crowley, D. M., Bates, J. E., Pettit, G. S., Lansford, J. E., Dick, D. M., & Dodge, K. A. (2015) · Development and Psychopathology · doi:10.1017/s095457941400131x · Cited by 25
“Dysregulated glucocorticoid signaling has been implicated in child and adult manifestations of externalizing psychopathology (McBurnett et al., 1991; Hawes et al., 2009; Lopez-Duran et al., 2009; Savitz et al., 2009; Stadler et al. 2010; van Zuiden et al. 2011; Fardet et al., 2012).”
Bülbüloğlu, S., & Demir, B. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101475 · Cited by 25
The cortisol:C-reactive protein ratio and negative affect reactivity in depressed adults.
Suarez, E. C., & Sundy, J. S. (2017) · Health Psychology · doi:10.1037/hea0000517 · Cited by 24
Lopes, M. W., Leal, R. B., Guarnieri, R., Schwarzbold, M. L., Hoeller, A., Diaz, A. P., Boos, G. L., Lin, K., Linhares, M. N., Nunes, J. C., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.251 · Cited by 23
Association of asthma and bipolar disorder: A nationwide population-based study in Taiwan
Lin, T.-C., Lee, C. T., Lai, T.-J., Lee, C.-T., Lee, K.-Y., Chen, V. C., & Stewart, R. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.033 · Cited by 23
“In a large cohort study by Fardet, the risk of mania increased over fivefold following glucocorticoid therapy (Fardet et al., 2012).”
BackgroundImmunosuppression following organ transplantation. Part 2: complications and their management
Cajanding, R. J. M. (2018) · British Journal of Nursing · doi:10.12968/bjon.2018.27.18.1059 · Cited by 23
van Hulst, A. M., Peersmann, S. H. M., van den Akker, E. L. T., Schoonmade, L. J., van den Heuvel‐Eibrink, M. M., Grootenhuis, M. A., & van Litsenburg, R. R. L. (2021) · Psycho-Oncology · doi:10.1002/pon.5654 · Cited by 22
“Most (6/8) studies of which four of higher quality did not find a difference between dexamethasone and prednisone with regard to developing APRs.4,25,37,38,43,47,51 This is in line with a previous review investigating neuropsychological side effects of dexamethasone versus prednisone.10 Oppositely, two other high qual…”
BackgroundInfluentialBroberg, B. V., Sommer, I. E., Benros, M. E., Glenthoj, B. Y., Gasse, C., & Köhler‐Forsberg, O. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.007 · Cited by 22
Is there a link between treatments with exogenous corticosteroids and dog behaviour problems?
Notari, L., Burman, O. H. P., & Mills, D. S. (2016) · Veterinary Record · doi:10.1136/vr.103768 · Cited by 21
Rao, R., Scherholz, M. L., & Androulakis, I. P. (2018) · Chronobiology International · doi:10.1080/07420528.2018.1498098 · Cited by 21
“Consistent with clinical manifestations due to cortisol exposure outside the normal physiological range, patients receiving synthetic GCs are at an increased risk of developing psychiatric disorders like depression, drug-induced hyperglycemia, longterm diabetes mellitus, osteoporosis, gastritis and cardiovascular dise…”
BackgroundGlucocorticoid production in the thymus and brain: Immunosteroids and neurosteroids
Salehzadeh, M., & Soma, K. K. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100352 · Cited by 21
Demir, B., & Bülbüloğlu, S. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101468 · Cited by 21
Resolution of depression: Antidepressant actions of resolvins
Deyama, S., Kaneda, K., & Minami, M. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.10.006 · Cited by 19
Asthma and other allergic diseases in relation to suicidal behavior among South Korean adolescents
Han, C. H., & Chung, J. H. (2018) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2018.10.015 · Cited by 19
Nasib, L. G., Gangadin, S. S., Rossum, I. W.-V., Boudewijns, Z. S. R. M., de Witte, L. D., Wilting, I., Luykx, J. J., Somers, M., Veen, N. D., van Baal, C. G. C. M., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.01.024 · Cited by 18
Psycho-Behavioural Changes in Dogs Treated with Corticosteroids: A Clinical Behaviour Perspective
Notari, L., Kirton, R., & Mills, D. S. (2022) · Animals · doi:10.3390/ani12050592 · Cited by 18
“In line with the human literature [56], it seems reasonable to suggest that the risk of behavioural side effects from these drugs is likely to be more severe in dogs with preexisting behavioural problems, and owners should be informed and fully advised of the associated risks accordingly.”
BackgroundLongitudinal hair cortisol in bipolar disorder and a mechanism based on HPA dynamics
Milo, T., Maimon, L., Cohen, B., Haran, D., Segman, D., Danon, T., Bren, A., Mayo, A., Rappaport, G. C., McInnis, M. G., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109234 · Cited by 17
Maschio, M. C. E., Perversi, F., & Maialetti, A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1480900 · Cited by 17
Vascular endothelial growth factor: a key factor in the onset and treatment of depression
Wang, J., Meng, F., Wang, L., & Li, Z. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1645437 · Cited by 17
“Secondly, large-scale clinical data analysis showed that treatment with synthetic glucocorticoids (e.g., prednisolone) increases the risk of MDD by 3-fold and the risk of suicide by 7-fold in patients (Fardet et al., 2012; Patten, 2000).”
Corticosteroid refractory sarcoidosis
Goldman, C., & Judson, M. A. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106081 · Cited by 17
Orabi, S. H., Allam, T. S., Shawky, S. M., Tahoun, E. A. E.-A., Khalifa, H. K., Almeer, R., Abdel‐Daim, M. M., El-Borai, N. B., & Mousa, A. (2020) · Biology · doi:10.3390/biology9110352 · Cited by 17
Introduction to Epigenetics in Psychiatry
Lee, R. S., & Avramopoulos, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417114-5.00001-2 · Cited by 16
Fardet, L. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2013.02.031 · Cited by 16
Self-citationAn Epidemiological Approach to “Steroid Psychosis”
Brown, E. S. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020181 · Cited by 16
Metadata
- Authors
- Fardet, L., Petersen, I., & Nazareth, I.
- Affiliations
- The Royal Free Hospital (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2012-05
- Volume
- 169
- Issue
- 5
- Pages
- 491-497
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1972710070
- Semantic Scholar
- 685aae4b79751dcc2039c2233ce3afa9e737b047
- Cited by
- 287
- References
- 35
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 18 · 2023: 20 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 9 · 2018: 40 · 2017: 18 · 2016: 23 · 2015: 15 · 2014: 21 · 2013: 13 · 2012: 7
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- glucocorticoids, suicidal behavior, suicide attempts, neuropsychiatric disorders, depression, mania, delirium, panic disorder, adverse drug reactions, primary care, incidence, risk factors, glucocorticoid dose, older men, young men, patient education, adverse event monitoring, primary care prescribing, pharmacovigilance, antipsychotic prescribing
- MeSH terms
- Mental Disorders, Bipolar Disorder, Confusion, Delirium, Depression, Female, Glucocorticoids, United Kingdom, Humans, Male, Middle Aged, Primary Health Care, Risk Factors, Suicide, Suicide, Attempted, Proportional Hazards Models, Panic Disorder
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.